Functional validation of somatic variability in <i>TP53</i> and <i>KRAS</i> for prediction of platinum sensitivity and prognosis in epithelial ovarian carcinoma patients.

Cancer Biol Ther · 2025 · PMC12341051 · PMID 40785058

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an increasing trendno p-value reported

This analysis revealed an increasing trend in the ratio TP53 / KRAS mutability: HGSC > > clear cell ≈ mucinous > endometrioid > > LGSC.

also in 63,971 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.

Functional validation of somatic variability in &lt;i&gt;TP53&lt;/i&gt; and &lt;i&gt;KRAS&lt;/i&gt; for prediction of platinum sensitivity and prognosis in epithelial ovarian carcinoma patients.

The sentences

Functional validation of somatic variability in <i>TP53</i> and <i>KRAS</i> for prediction of platinum sensitivity and prognosis in epithelial ovarian carcinoma patients.